10-Q: Beyond Air Reports Q2 2026 Results, Faces Funding Concerns

Beyond Air, Inc. filed its Q2 2026 Form 10-Q, detailing continued operational losses and significant cash outflows, raising substantial doubt about its ability to meet obligations without further financing.

Summary

• Beyond Air, Inc. reported its financial results for the quarter and six months ended September 30, 2026.
• The company experienced net losses of $8.18 million for the three months and $16.33 million for the six months ended September 30, 2026.
• Total assets were $36.26 million, with total liabilities of $30.13 million, resulting in total stockholders' equity of $6.12 million.
• Cash, cash equivalents, and marketable securities totaled $18.54 million as of September 30, 2026.
• The company used $10.51 million in operating activities during the first six months of fiscal year 2026.
• Management believes substantial doubt exists about the company's ability to continue as a going concern and requires additional funding within one year.
• The company completed a 1-for-20 reverse stock split effective July 13, 2026, to regain compliance with Nasdaq's minimum bid price requirement.
• The company is developing its LungFit platform for various respiratory conditions and has other programs in oncology (Beyond Cancer) and neurology (NeuroNOS).

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the significant net losses, ongoing cash burn, and substantial doubt about the company's ability to continue as a going concern without additional funding.

Positives

• Revenue increased to $2.32 million in Q2 2026 from $1.82 million in Q2 2025.
• Gross profit was $0.20 million in Q2 2026, an improvement from a gross loss of $0.30 million in Q2 2025.
• The company regained compliance with Nasdaq's minimum bid price requirement after a reverse stock split.
• The LungFit PH system received European CE mark approval in November 2024 and has received regulatory approvals in over 27 countries outside the US and EU.
• The FDA granted Breakthrough Device Designation to LungFit GO for the treatment of NTM-Pulmonary Disease in August 2026.
• The company received $9.1 million in net proceeds from a private placement in July 2026.
• The company's nNOS investigational therapy, BA-102, received Orphan Drug Designation for Phelan-McDermid Syndrome in April 2025.
• The company's nNOS investigational therapy, BA-101, received Orphan Drug Designation for Glioblastoma in September 2025.

Negatives

• The company incurred a net loss of $8.18 million for the three months ended September 30, 2026, and $16.33 million for the six months ended September 30, 2026.
• Operating cash flow used $10.51 million in the first six months of fiscal year 2026.
• As of September 30, 2026, the company had $13.7 million in cash, cash equivalents, and marketable securities, with management concluding that additional funding is required within one year.
• The company has an accumulated deficit of $335.3 million as of September 30, 2026.
• Interest and finance expenses increased significantly to $1.50 million in Q2 2026 from $0.64 million in Q2 2025.
• A $0.57 million charge was incurred for scrapped materials by a contract manufacturer.
• The company is subject to Nasdaq's Discretionary Panel Monitor for one year following regaining compliance with the minimum bid price rule.
• The company's common stock has undergone two 1-for-20 reverse stock splits within a two-year period, indicating potential ongoing struggles with market valuation.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern, requiring additional funding within one year.
• Failure to maintain compliance with Nasdaq's continued listing standards could result in delisting, adversely affecting liquidity, market price, and the ability to raise capital.
• The company's future capital needs are significant and depend on the success of commercialization, clinical trials, and regulatory approvals.
• The company is dependent on third-party suppliers, with a high concentration of purchases from two vendors.
• Regulatory approvals for product candidates in foreign jurisdictions are not assured and delays could have a material adverse impact.
• The company faces risks related to new technological innovations, protection of proprietary technology, and product liability.
• The company's ability to successfully manage its growth as a commercial-stage company is a key risk factor.
• The company's stock price may decline following reverse stock splits, and further delisting could significantly impair the value of investments.

Future Outlook

The company expects to incur net losses and significant cash outflows for at least the next year, requiring additional funding within one year. Management is confident in arranging financing, but there is no assurance it will be available on acceptable terms. Future capital needs depend on commercialization success, clinical trial costs, and regulatory approvals.

Management Comments

• Management believes that the factors detailed in the filing raise substantial doubt about the Company's ability to meet its obligations with cash on hand and concluded that the Company will require additional funding within one year from the date these unaudited condensed consolidated financial statements are issued.
• Management is confident that the efforts to arrange financing, while not assured, will enable the Company to meet its obligations.
• There can be no assurance that additional financing will be available when needed or on acceptable terms.
• The Company's future capital needs and the adequacy of its available funds will depend on many factors, including, but not necessarily limited to, the success and costs of commercialization of the Companys approved product and the actual cost and time necessary for current and anticipated preclinical studies, clinical trials and other actions needed to obtain certification or regulatory approval of the Companys product candidates.

Industry Context

StockSavvy.ai notes that Beyond Air operates in the highly competitive and capital-intensive medical device and biopharmaceutical sectors. The company's focus on nitric oxide (NO) technology for respiratory and other conditions places it in a niche but potentially high-growth area. However, the significant R&D costs, lengthy regulatory approval processes, and the need for substantial ongoing funding are common challenges faced by companies in this industry.

Comparison to Industry Standards

• The company's revenue of $4.1 million for the first six months of 2026 is modest compared to established medical device companies, reflecting its commercial-stage but still developing market penetration.
• The significant net loss of $16.3 million for the same period is not uncommon for early-stage biopharmaceutical and medical device companies investing heavily in R&D and commercialization, but the scale of the loss relative to revenue raises concerns.
• The company's cash burn rate of $10.5 million for the six months ended September 30, 2026, highlights the substantial capital required to operate in this industry, necessitating continuous fundraising efforts.
• The need for additional funding within one year is a critical concern, as many companies in this sector struggle to secure sufficient capital to reach profitability or commercial viability.
• The company's reliance on third-party suppliers for critical components, with a high concentration from two vendors, presents a risk common in manufacturing-dependent industries, where supply chain disruptions can be impactful.

Legal Proceedings

• No legal proceedings are expected to have a material effect on the company's financial position, cash flows, or results of operations.

Related Party Transactions

• On June 2, 2025, the company received $2.0 million of advanced financing from Robert Carey, a related party, director, and existing lender under its Loan Agreement.
• The Loan Agreement for $11.5 million included lenders such as former CEO Steven Lisi and director Robert Carey.
• In the July 2026 private placement, the company sold shares and warrants to CEO Robert Goodman and CFO Daniel Moorhead at a slightly higher price than institutional investors.

Stakeholder Impact

• Shareholders face continued dilution risk due to ongoing need for capital raises and potential stock price volatility related to Nasdaq listing concerns.
• Employees may face uncertainty regarding job security due to the company's going concern issues and need for funding.
• Creditors and lenders may be concerned about the company's ability to meet its debt obligations given its cash burn and accumulated deficit.
• Suppliers may face payment delays or increased scrutiny due to the company's financial condition.

Next Steps

• Continue commercialization efforts for the LungFit PH system in the U.S.
• Pursue regulatory approvals and market expansion in countries outside the U.S. and EU.
• Advance preclinical and clinical development for other product candidates, subject to financing.
• Seek additional financing to fund operations and development activities.
• Monitor compliance with Nasdaq listing requirements and the Discretionary Panel Monitor.

Key Dates

Recommendation

The company shows progress in revenue and product development (LungFit PH approvals, Breakthrough Designation for LungFit GO), but the significant net losses, substantial cash burn, and the 'going concern' warning are major red flags. The ongoing need for capital raises and the Nasdaq listing risks create considerable uncertainty. While there's potential in its technology, the immediate financial precariousness warrants a cautious 'hold' stance until a clearer path to profitability and sustainable funding is established.

Keywords

Beyond Air, Form 10-Q, LungFit PH, Nitric Oxide, Medical Device, Biopharmaceutical, PPHN, Clinical Trials